Otsuka Submits NDA For TB Drug Delamanid in Europe
This article was originally published in PharmAsia News
Otsuka Pharmaceutical Co. Ltd has filed a new drug application for anti-tuberculosis delamanid (OPC-67683) in Europe. The agent is to treat patients with multi-drug resistant TB.
You may also be interested in...
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway